R Razzak1, E L R Bédard1, J O Kim2, S Gazala1, L Guo3, S Ghosh3, A Joy3, T Nijjar3, E Wong3, W H Roa4. 1. Division of Thoracic Surgery, Department of Surgery, University of Alberta, Edmonton, AB; 2. Department of Radiation Oncology, CancerCare Manitoba, and University of Manitoba, Winnipeg, MB; 3. Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, AB; 4. Division of Pulmonary Medicine, Department of Internal Medicine, University of Alberta Hospital and University of Alberta, Edmonton, AB.
Abstract
BACKGROUND: Non-small-cell lung cancer (nsclc) is associated with very poor overall survival because 70% of patients present with locally advanced or metastatic disease at the time of diagnosis. Micrornas (mirnas) are a class of short, noncoding rna molecules whose presence in samples of biologic fluids such as sputum has demonstrated promise as a potential means of detecting nsclc. We investigated the stage-specific nsclc detection potential of an efficient panel of 3 mirnas (mir-21, mir-210, mir-372) using a single sputum sample. METHODS: A single spontaneously expectorated sputum sample was prospectively collected from 21 early nsclc (≤stage ii) patients, 22 advanced nsclc (≥stage iii) patients, and 10 control subjects. Mirna expression profiles were determined by quantitative real-time polymerase chain reaction and were analyzed by unsupervised hierarchical cluster analysis. RESULTS: Mean tumour size (±95% confidence interval) in the early and advanced nsclc patients was 3.3 cm ± 0.9 cm and 4.8 cm ± 0.7 cm respectively. Adenocarcinoma constituted 61.9% of the early and 45.5% of the advanced nsclc cases respectively. In comparing the early nsclc group with the control group, the mirna panel yielded a diagnostic sensitivity of 67% and a specificity of 90.0%. For the advanced nsclc group, the mirna panel detected nsclc with a sensitivity and specificity of 64% and 100% respectively. CONCLUSIONS: A sputum mir-21, mir-210, and mir-372 expression profile might provide a sensitive and highly specific means for detecting nsclc. Sputum mirna analysis demonstrates promise as a potential complementary screening tool.
BACKGROUND:Non-small-cell lung cancer (nsclc) is associated with very poor overall survival because 70% of patients present with locally advanced or metastatic disease at the time of diagnosis. Micrornas (mirnas) are a class of short, noncoding rna molecules whose presence in samples of biologic fluids such as sputum has demonstrated promise as a potential means of detecting nsclc. We investigated the stage-specific nsclc detection potential of an efficient panel of 3 mirnas (mir-21, mir-210, mir-372) using a single sputum sample. METHODS: A single spontaneously expectorated sputum sample was prospectively collected from 21 early nsclc (≤stage ii) patients, 22 advanced nsclc (≥stage iii) patients, and 10 control subjects. Mirna expression profiles were determined by quantitative real-time polymerase chain reaction and were analyzed by unsupervised hierarchical cluster analysis. RESULTS: Mean tumour size (±95% confidence interval) in the early and advanced nsclc patients was 3.3 cm ± 0.9 cm and 4.8 cm ± 0.7 cm respectively. Adenocarcinoma constituted 61.9% of the early and 45.5% of the advanced nsclc cases respectively. In comparing the early nsclc group with the control group, the mirna panel yielded a diagnostic sensitivity of 67% and a specificity of 90.0%. For the advanced nsclc group, the mirna panel detected nsclc with a sensitivity and specificity of 64% and 100% respectively. CONCLUSIONS: A sputum mir-21, mir-210, and mir-372 expression profile might provide a sensitive and highly specific means for detecting nsclc. Sputum mirna analysis demonstrates promise as a potential complementary screening tool.
Authors: Asha Sarma; Marta E Heilbrun; Karen E Conner; Scott M Stevens; Scott C Woller; C Gregory Elliott Journal: Chest Date: 2012-09 Impact factor: 9.410
Authors: Wha Ja Cho; Jeong Min Shin; Jong Soo Kim; Man Ryul Lee; Ki Sung Hong; Jun-Ho Lee; Kyoung Hwa Koo; Jeong Woo Park; Kye-Seong Kim Journal: Mol Cells Date: 2009-11-19 Impact factor: 5.034
Authors: Wilson H Roa; Julian O Kim; Rene Razzak; Hongfei Du; Linghong Guo; Ravinder Singh; Sayf Gazala; Sunita Ghosh; Eric Wong; Anil A Joy; James Z Xing; Eric L Bedard Journal: Clin Invest Med Date: 2012-10-06 Impact factor: 0.825
Authors: G J Weiss; L T Bemis; E Nakajima; M Sugita; D K Birks; W A Robinson; M Varella-Garcia; P A Bunn; J Haney; B A Helfrich; H Kato; F R Hirsch; W A Franklin Journal: Ann Oncol Date: 2008-02-27 Impact factor: 32.976
Authors: Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce Journal: Proc Natl Acad Sci U S A Date: 2006-02-03 Impact factor: 11.205